The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Open accessAbstract
Increasing prevalence and severity of multi-drug-resistant (MDR) bacterial infections has necessitated novel antibacterial strategies. Ideally, new approaches would target bacterial pathogens while exerting selection for reduced pathogenesis when these bacteria inevitably evolve resistance to therapeutic intervention. As an example of such a management strategy, we isolated a lytic bacteriophage, OMKO1, (family Myoviridae) of Pseudomonas aeruginosa that utilizes the outer membrane porin M (OprM) of the multidrug efflux systems MexAB and MexXY as a receptor-binding site. Results show that phage selection produces an evolutionary trade-off in MDR P. aeruginosa, whereby the evolution of bacterial resistance to phage attack changes the efflux pump mechanism, causing increased sensitivity to drugs from several antibiotic classes. Although modern phage therapy is still in its infancy, we conclude that phages, such as OMKO1, represent a new approach to phage therapy where bacteriophages exert selection for MDR bacteria to become increasingly sensitive to traditional antibiotics. This approach, using phages as targeted antibacterials, could extend the lifetime of our current antibiotics and potentially reduce the incidence of antibiotic resistant infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MUSCLE: multiple sequence alignment with high accuracy and high throughput
Edgar, R. C. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh340 · Cited by 44,662
RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models
Stamatakis, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl446 · Cited by 15,582
PAML: a program package for phylogenetic analysis by maximum likelihood
Yang, Z. (1997) · Bioinformatics · doi:10.1093/bioinformatics/13.5.555 · Cited by 5,373
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman, F. S. L., Hufnagle, W. O., Kowalik, D. J., Lagrou, M., et al. (2000) · Nature · doi:10.1038/35023079 · Cited by 4,573
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.649-659.2001 · Cited by 1,566
Cosgrove, S. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499406 · Cited by 1,271
Comprehensive transposon mutant library of Pseudomonas aeruginosa
Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C., Levy, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036282100 · Cited by 1,126
Pseudomonas Aeruginosa: Resistance to the Max
Poole, K. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00065 · Cited by 948
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Self-citationWright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., & Nishino, T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3322-3327.2000 · Cited by 722
Multidrug-Resistant Pseudomonas aeruginosa : Risk Factors and Clinical Impact
Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.43-48.2006 · Cited by 617
de Kraker, M. E. A., Davey, P. G., Grundmann, H., & on behalf of the BURDEN study group (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001104 · Cited by 599
AUREOMYCIN: A PRODUCT OF THE CONTINUING SEARCH FOR NEW ANTIBIOTICS
Duggar, B. M. (1948) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1948.tb27262.x · Cited by 512
Summers, W. C. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.437 · Cited by 474
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A. (2009) · Journal of Wound Care · doi:10.12968/jowc.2009.18.6.42801 · Cited by 468
Li, X. Z., Livermore, D. M., & Nikaido, H. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.8.1732 · Cited by 402
Clinical and economic burden of antimicrobial resistance
Maragakis, L. L., Perencevich, E. N., & Cosgrove, S. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.751 · Cited by 329
Falagas, M. E., & Karageorgopoulos, D. E. (2008) · Clinical Infectious Diseases · doi:10.1086/528867 · Cited by 290
Contribution of the MexX-MexY-OprM Efflux System to Intrinsic Resistance in Pseudomonas aeruginosa
Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., & Nishino, T. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2242-2246.2000 · Cited by 279
Genome Diversity of Pseudomonas aeruginosa PAO1 Laboratory Strains
Klockgether, J., Munder, A., Neugebauer, J., Davenport, C. F., Stanke, F., Larbig, K. D., Heeb, S., Schöck, U., Pohl, T. M., Wiehlmann, L., et al. (2010) · Journal of Bacteriology · doi:10.1128/jb.01515-09 · Cited by 273
de Kraker, M. E. A., Wolkewitz, M., Davey, P. G., & Grundmann, H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01157-10 · Cited by 240
Jalal, S., Ciofu, O., Høiby, N., Gotoh, N., & Wretlind, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.710-712.2000 · Cited by 236
Chan, B. K., & Abedon, S. T. (2012) · Advances in Applied Microbiology · doi:10.1016/b978-0-12-394805-2.00001-4 · Cited by 212
Self-citationOuter Membranes and Efflux: The Path to Multidrug Resistance in Gram- Negative Bacteria
Poole, K. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378454 · Cited by 198
MexXY multidrug efflux system of Pseudomonas aeruginosa
Morita, Y., Tomida, J., & Kawamura, Y. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00408 · Cited by 196
Mikkelsen, H., McMullan, R., & Filloux, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029113 · Cited by 191
Cole, S. J., Records, A. R., Orr, M. W., Linden, S. B., & Lee, V. T. (2014) · Infection and Immunity · doi:10.1128/iai.01652-14 · Cited by 188
Morita, Y., Sobel, M. L., & Poole, K. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.5.1847-1855.2006 · Cited by 158
Cao, B., Wang, H., Sun, H., Zhu, Y., & Chen, M. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.021 · Cited by 143
Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa
Higgins, P. G. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00009-8 · Cited by 138
Sex and the Evolution of Intrahost Competition in RNA Virus φ6
Turner, P. E., & Chao, L. (1998) · Genetics · doi:10.1093/genetics/150.2.523 · Cited by 131
Self-citationRisk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer
Ohmagari, N., Hanna, H. A., Graviss, L. S., Hackett, B. C., Perego, C., González, V., Dvorak, T. L., Hogan, H., Hachem, R. Y., Rolston, K. V., et al. (2005) · Cancer · doi:10.1002/cncr.21115 · Cited by 107
Kukavica‐Ibrulj, I., Bragonzi, A., Paroni, M., Winstanley, C., Sanschagrin, F., O’Toole, G. A., & Lévesque, R. C. (2007) · Journal of Bacteriology · doi:10.1128/jb.01572-07 · Cited by 102
Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms
Zhang, Q., & Buckling, A. (2012) · Evolutionary Applications · doi:10.1111/j.1752-4571.2011.00236.x · Cited by 99
Introducing yesterday‘s phage Therapy in today‘s Medicine
Pirnay, J., Verbeken, G., Rose, T., Jennes, S., Zizi, M., Huys, I., Lavigne, R., Merabishvili, M., Vaneechoutte, M., Buckling, A., et al. (2012) · Future Virology · doi:10.2217/fvl.12.24 · Cited by 95
The evolution of life history trade-offs in viruses
Goldhill, D. H., & Turner, P. E. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.005 · Cited by 91
Self-citationCRISPR-mediated phage resistance and the ghost of coevolution past
Vale, P. F., & Little, T. J. (2010) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2010.0055 · Cited by 87
Ojala, V., Laitalainen, J., & Jalasvuori, M. (2013) · Evolutionary Applications · doi:10.1111/eva.12076 · Cited by 82
Dessau, M., Goldhill, D. H., McBride, R. L., Turner, P. E., & Modis, Y. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003102 · Cited by 68
Self-citationMiró, E., Navarro, F., Mirelis, B., Sabaté, M., Rivera, A., Coll, P., & Prats, G. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3991-3994.2002 · Cited by 41
Queenan, A. M., Shang, W., Bush, K., & Flamm, R. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00060-10 · Cited by 28
Lytic phages obscure the cost of antibiotic resistance in Escherichia coli
Tazzyman, S. J., & Hall, A. R. (2014) · The ISME Journal · doi:10.1038/ismej.2014.176 · Cited by 22
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Oechslin, F. (2018) · Viruses · doi:10.3390/v10070351 · Cited by 594
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Roach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Metadata
- Authors
- Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E.
- Venue
- Scientific Reports
- Published
- 2016-05-26
- Volume
- 6
- Issue
- 1
- Pages
- 26717-26717
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2399110743
- Cited by
- 715
- References
- 44
- FWCI
- 36.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.